IPIX (IPIX) Stock Price & Analysis
IPIX (IPIX) rose 0.00% to USD 0 as of July 25, 2026 at 11:15 UTC, according to Nexqual real-time market data.
IPIX last closed at USD 0; the session ranged USD 0–0.01 on volume of 12,600 shares. Market capitalization is $1.40M, with a 52-week range of USD 0–0.05 (PNK). Source: Nexqual, July 25, 2026 at 11:15 UTC.
Key Statistics (as of July 25, 2026 at 11:15 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0.01 |
| Day Range | USD 0 – 0.01 |
| 52-Week Range | USD 0 – 0.05 |
| Volume | 12,600 shares |
| Market Cap | $1.40M |
| Exchange | PNK |
Technical Analysis (IPIX)
Nexqual's technical model rates IPIX "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 11:15 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 67.39 (neutral) |
| vs SMA50 | Above (USD 0) |
| MACD | 0 (positive) |
Analyst Ratings (IPIX)
Wall Street analysts rate IPIX "None", per Nexqual as of July 25, 2026 at 11:15 UTC.
| Consensus Rating | None |
|---|
Earnings (IPIX)
Source: Nexqual, July 25, 2026 at 11:15 UTC.
Financials & Fundamentals (IPIX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -114.34% |
| Debt / Equity | 59.81 |
| Current Ratio | 0.19 |
| Total Cash | $864,000 |
| Total Debt | $695,000 |
| Free Cash Flow | $-986,375 |
Source: Nexqual, July 25, 2026 at 11:15 UTC.
Financial Health Score (IPIX)
Nexqual rates IPIX's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 11:15 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $864K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$2M |
| Efficiency | Critical — ROE -114%, ROA -18.4% |
Ownership (IPIX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 514.01M |
| Float | 514.10M |
Source: Nexqual, July 25, 2026 at 11:15 UTC.
Leadership (IPIX)
IPIX is led by Leo Ehrlich (age 67), Chairman, CEO, CFO, Principal Accounting Officer & Secretary, per Nexqual as of July 25, 2026 at 11:15 UTC.
| Chairman, CEO, CFO, Principal Accounting Officer & Secretary | Leo Ehrlich (age 67) |
|---|---|
| Senior Vice President of Clinical Sciences & Portfolio Management | Jane Harness M.S., MP (age 57) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MAMA | Mama's Creations, Inc. | USD 17.74 | ▲ 3.02% |
| SYNX | Silynxcom Ltd. | USD 1.06 | ▲ 0.95% |
| NGEN | NervGen Pharma Corp. | USD 1.63 | ▼ 5.23% |
| CYDY | CytoDyn Inc. | USD 0.2 | ▲ 0% |
| DECN | DECISION DIAGNOSTICS CORP | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 11:15 UTC. This page is informational and not investment advice.